Blockchain Registration Transaction Record

Nutriband Announces 25% Preferred Stock Dividend Linked to FDA Approval

Nutriband Inc. announces a 25% preferred stock dividend, with shares convertible upon FDA approval of its AVERSA Fentanyl product, showcasing its abuse-deterrent technology.

This news is pivotal for investors and the healthcare sector alike, as it underscores Nutriband's innovative approach to combating drug abuse through its AVERSA technology. The potential FDA approval of the AVERSA Fentanyl product could mark a significant milestone in the fight against the opioid crisis, offering a safer alternative to traditional fentanyl patches. For shareholders, the dividend represents not just a financial incentive but also a vote of confidence in the company's future growth and its contribution to public health.